ArticleBioinformatics (Oxford, England)2023
iGRLDTI: an improved graph representation learning method for predicting drug-target interactions over heterogeneous biological information network.
Article in Bioinformatics (Oxford, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed.
- CAREPath: semantic context-aware reasoning paths with mechanism-augmented embeddings for drug repurposing.Briefings in bioinformatics · 2026Article
- Graph-based drug-target interaction modeling: from representation learning to output-driven drug discovery.Briefings in bioinformatics · 2026Review
- G2DR: a genotype-first framework for genetics-informed target prioritization and drug repurposing.Briefings in bioinformatics · 2026Article
- A graph retrieval-augmented generation pipeline for systematic drug target discovery: validation and application to ocular neovascularization.Briefings in bioinformatics · 2026Article
- SSAS-GO: structure-sequence adaptive synergy network for protein function prediction.Briefings in bioinformatics · 2026Article
- A case-based explainable graph neural network framework for mechanistic drug repositioning.Bioinformatics (Oxford, England) · 2026Article
- TriDTI: tri-modal representation learning with cross-modal alignment for drug-target interaction prediction.Briefings in bioinformatics · 2026Article
- Article
- Heterogeneous biological graph convolutional network for drug-target interaction prediction.PloS one · 2026Article
- Heterogeneous Network With Multiview Path Aggregation: Drug-Target Interaction Prediction Study Design.JMIR medical informatics · 2025Article
- A survey on deep learning for drug-target binding prediction: models, benchmarks, evaluation, and case studies.Briefings in bioinformatics · 2025Review
- An inductive learning-based method for predicting drug-gene interactions using a multi-relational drug-disease-gene graph.Journal of pharmaceutical analysis · 2025Article
- NASNet-DTI: accurate drug-target interaction prediction using heterogeneous graphs and node adaptation.Briefings in bioinformatics · 2025Article
- Ensemble learning methods and heterogeneous graph network fusion: building drug-gene-disease triple association prediction models.Briefings in bioinformatics · 2025Article
- Adaptive multi-view learning method for enhanced drug repurposing using chemical-induced transcriptional profiles, knowledge graphs, and large language models.Journal of pharmaceutical analysis · 2025Article
- HNF-DDA: subgraph contrastive-driven transformer-style heterogeneous network embedding for drug-disease association prediction.BMC biology · 2025Article
- Drug-target binding affinity prediction based on power graph and word2vec.BMC medical genomics · 2025Article
- Enhancing drug-target interaction prediction with graph representation learning and knowledge-based regularization.Frontiers in bioinformatics · 2025Article
- Article
- Drug target affinity prediction based on multi-scale gated power graph and multi-head linear attention mechanism.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
motivationThe task of predicting drug-target interactions (DTIs) plays a significant role in facilitating the development of novel drug discovery. Compared with laboratory-based approaches, computational methods proposed for DTI prediction are preferred due to their high-efficiency and low-cost advantages. Recently, much attention has been attracted to apply different graph neural network (GNN) models to discover underlying DTIs from heterogeneous biological information network (HBIN). Although GNN-based prediction methods achieve better performance, they are prone to encounter the over-smoothing simulation when learning the latent representations of drugs and targets with their rich neighborhood information in HBIN, and thereby reduce the discriminative ability in DTI prediction.
resultsIn this work, an improved graph representation learning method, namely iGRLDTI, is proposed to address the above issue by better capturing more discriminative representations of drugs and targets in a latent feature space. Specifically, iGRLDTI first constructs an HBIN by integrating the biological knowledge of drugs and targets with their interactions. After that, it adopts a node-dependent local smoothing strategy to adaptively decide the propagation depth of each biomolecule in HBIN, thus significantly alleviating over-smoothing by enhancing the discriminative ability of feature representations of drugs and targets. Finally, a Gradient Boosting Decision Tree classifier is used by iGRLDTI to predict novel DTIs. Experimental results demonstrate that iGRLDTI yields better performance that several state-of-the-art computational methods on the benchmark dataset. Besides, our case study indicates that iGRLDTI can successfully identify novel DTIs with more distinguishable features of drugs and targets. AVAILABILITY AND IMPLEMENTATION: Python codes and dataset are available at https://github.com/stevejobws/iGRLDTI/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.